translocations are found in 70% of infant leukaemia’s less than 2 years of age1.Various studies have that In mixed
lineage leukemia balanced chromosome translocations occurs lead to expression
of leukemia promoting genes2.Various cellular proteins like
PI3K, GSK3?, mTOR, cyclin dependent kinases, histone deacetylases and histone
methyltransferases are targeted for the treatment of mixed lineage leukemia.
Keywords-Mixed lineage leukemia, translocation,
PI3K, mTOR, histone methyltransferase.
Mixed Lineage Leukemia pathology associated with
haemopoetic cells is under a hot bebate from the last two decades. MLL
associated translocations are found in 70% of infant leukaemia’s under the age
of 2 years with a very poor prognosis1. Mixed lineage
leukemia display co-expression of lymphoid as well as myeloid antigens hence
infants with MLL translocation show both myeloid and lymphoid blast cell population3. Normally, the
MLL gene encodes for a SET domain histone methyltransferase that catalyzes the
methylation of lysine 4 of histone H3 (H3K4) at particular regions 4. In MLL, the catalytic
SET domain responsible for Histone 3 lysine 4 methyltransferase activity is
lost and the remaining MLL protein is fused to a variety of partners such as AF4, AF9,
AF10 and ENL by balanced chromosomal translocations and rearrangements2. Amino terminal
portion of MLL protein is fused to fifty distinct binding partners 5.The fusion
products retain the abilty to locate gene specific recognition regions even after translocation and interact directly
or indirectly with other histone methyltransferaes
like DOTIL6. DOT1L
interacts with six unique MLL fusion proteins created by chromosomal translocations
i.e. MLL-AF4, MLL-AF9, MLL-ENL, MLL-AF10, SET-NUP214, CALM-AF107.The fusion
products gain the ability to recruit Dot1L to the aberrant gene regions and
increase the expression of genes responsible for promotion of leukaemia 8.There is still
lack of good quality therapeutics for mixed lineage leukemia due to lack of
small molecule inhibitors that will directly target MLL9.The focus of
the review will be on the recent published work as well as therapeutic targets
from the last 2 decades.
PI3K as a therapeutic target of MLL
reports have shown that Simaltaneous inhibition of PI3K/mTOR has shows anticancer activity in MLL
rearranged leukaemias10. In vivo
PI3K/mTOR inhibition has shown to reduce
tumour progression and also shown to increase survival in MLL-AF9 xenograft
mouse model10.BEZ, rapamycin
and MK-2206 have shown good in vitro activity as well as have shown good
activity in mice tumour models by inhibiting PI3K, mTOR and AKT pathways10.
CDK4/CDK6 as a therapeutic target of MLL
MLL there is a cell differentiation block which can be broken by using small
molecules like CDK6 inhibitors11.CDK6 as a
therapeutic target for mixed lineage leukemia was identified by Plakle et al.,
201412. PD-0332991 is a dual
inhibitor of CDK4/CDK6 which is clinical trials for treatment of breast cancers as well as
PD-0332991 have shown strong growth inhibition in MLL rearranged leukemic cells 12. Current
treatment of MLL is chemotherapy and allogenic stem cell transplantation in
Small molecule inhibitors of histone deacetylases as treatment of MLL
has been shown recently that HDAC inhibitors induce apoptosis
in MLL rearranged cell by autophagy 14. Inhibition of
histone deacetylase by VPA (valproic acid) in cells harbouring MLL induced cell cycle arrest
(G1-phase) and apoptotic cell death in MLL-AF9 expressing cell lines15.
Retinoic acid and Vitamin D as important drugs for MLL
MLL-AF9 expressing leukemic cell line MOLM-14
undergoes differentiation when exposed to ATRA or 1, 25-dihydroxyvitamin D316. Simultaneous
treatment of MLL cells with Retinoic acid and epidrug 5-azacytidine has shown
to inhibit growth of MLL positive
Glycogen Synthase kinase 3 is an important target to control MLL
Synthase kinase3 has shown to support
MLL leukemia proliferation18.GSK3 inhibition
has shown to induce G1 growth arrest and
cell death in MLL transformed cells18. GSK3-?
inhibition has shown to increase survival in mouse model of MLL associated leukaemic
18. Specific GSK-3 inhibitor
SB-415286 has been repored to inhibit growth by induction of apoptosis in leukemic cells19.
of Sirt1 activators and DOT1L inhibitor for the treatment of mixed lineage
of SIRT1 and at same time inhibition of DOTIL has been shown be an effective therapy for mixed lineage leukemia20.SIRT1
activation mediated silencing of the
MLL-AF9 leukemia has been shown to be enhanced by simultaneous DOT1L inhibition20. SIRT1 activation
by SIRT1 activator SRT1720 in combination with DOTIL inhibitor has been
reported to augment apoptosis induction
in mixed lineage leukemia cells20.
VIII. ?-catenin as a therapeutic target of MLL
It has been reported that Leukemic stem cells have a more self renewal and drug résistance property 21. ?-catenin establishes the growth of mixed
lineage leukemia Leukemic stem cells22. Reversal of LSC to PLSC has shown to significantly
reduces the growth of mixed lineage
leukemia cells by ?-catenin downregulation or suppression 23.
IX. TET1 is a direct target of MLL-fusion proteins and
is an important therapeutic target
TET1 has shown to be highly expressed in MLL-rearranged leukemia cells with
leads to drastic increase of 5-hydroxymethylcytosine levels24.TET1 has shown to be an associated parter of
MLL which is leads to increased growth 24. Overexpressed of TET1 in MLL rearranged leukemia has shown to be
responsible for overexpression of leukemia promoting genes Hoxa9 Pbx3 and Meis1
25.TET1 overexpression has shown increases proliferation and inhibit cell death
of MLL cells26.Recent report suggested that TET1 knockdown
or therapeutic intervention of TET prevent MLL rearranged leukemia27.
BET family members and MLL
It has been shown that BET family members i.eBromodomainT,Bromodomain2,Bromodomain
3 and Bromodomain 4 recruit MLL fusion
oncogene proteins to diverged genic regions and increase the expression of leukemia inducing genes BCL2, CDK6 and C-MYC28. It has been
shown that inhibition of bromodomain proteins could provide a new novel approach
for the treatment of mixed lineage leukemia28 .
DOTIL inhibitors for the treatment of MLL
It has been shown that inhibition of DOTIL by small
molecules kill mixed lineage leukemia
cells by inhibiting H3K79 hypermethylation at the promoters of leukemia
promoting genes29. Inhibition of
DOT1L has shown to increase apoptosis in
cells carrying MLL rearrangement cells as well as in mouse model of MLL30. EPZ5676 and
EPZ004777 are the currently available DOT1L inhibitors which are in research
and development for the treatment of mixed lineage leukemia31.
XII. Lysine specific demethylase
inhibitors for the treatment of MLL
LSD1 is shown to be essential for
proliferation and growth of
leukemic stem cells containing MLL-Fused oncogenes32 LSD1 (Lysine
specific demethylase1) is shown to be highly up regulated in mixed lineage leukemia 32. It has been
shown that Lysine specific demethylase inhibitors promote differentiation and apoptotic cell
death of MLL cells33.
XIII. Menin and MLL interaction
Borkin et al.
recently developed potent inhibitors blocking interaction of leukemia associated
protein MLL and menin 34. These compounds showed to inhibit the growth of leukemia cells in vitro
as well as prolonged the survival of MLL leukemic mice34. Inhibiting the interaction between Menin and MLL has shown to cause downregulation of Hox A
genes and differentiation of MLL-Rearranged Leukemic cells34. Borkin et al.
Showed that MI-463 and MI-503 blocked the MLL
Menin interaction, resulted in increased cell
death and differentiation 34.
small molecule inhibitors are in research and development for the treatment of
mixed lineage leukemia. All Currently available treatments for mixed lineage leukemia
have low efficacy as well as high toxicity. So there is a need to develop new
drugs as well as to identify new therapeutic targets for mixed lineage leukemia.